235 related articles for article (PubMed ID: 1737029)
21. Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin.
Tager H; Thomas N; Assoian R; Rubenstein A; Saekow M; Olefsky J; Kaiser ET
Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3181-5. PubMed ID: 6997872
[TBL] [Abstract][Full Text] [Related]
22. Chiral mutagenesis of insulin. Foldability and function are inversely regulated by a stereospecific switch in the B chain.
Nakagawa SH; Zhao M; Hua QX; Hu SQ; Wan ZL; Jia W; Weiss MA
Biochemistry; 2005 Apr; 44(13):4984-99. PubMed ID: 15794637
[TBL] [Abstract][Full Text] [Related]
23. Non-standard insulin design: structure-activity relationships at the periphery of the insulin receptor.
Weiss MA; Wan Z; Zhao M; Chu YC; Nakagawa SH; Burke GT; Jia W; Hellmich R; Katsoyannis PG
J Mol Biol; 2002 Jan; 315(2):103-11. PubMed ID: 11779231
[TBL] [Abstract][Full Text] [Related]
24. Importance of the character and configuration of residues B24, B25, and B26 in insulin-receptor interactions.
Mirmira RG; Nakagawa SH; Tager HS
J Biol Chem; 1991 Jan; 266(3):1428-36. PubMed ID: 1988428
[TBL] [Abstract][Full Text] [Related]
25. Shortened insulin with enhanced in vitro potency.
Casaretto M; Spoden M; Diaconescu C; Gattner HG; Zahn H; Brandenburg D; Wollmer A
Biol Chem Hoppe Seyler; 1987 Jun; 368(6):709-16. PubMed ID: 3304338
[TBL] [Abstract][Full Text] [Related]
26. A structural switch in a mutant insulin exposes key residues for receptor binding.
Ludvigsen S; Olsen HB; Kaarsholm NC
J Mol Biol; 1998 May; 279(1):1-7. PubMed ID: 9636695
[TBL] [Abstract][Full Text] [Related]
27. Diabetes-associated mutations in human insulin: crystal structure and photo-cross-linking studies of a-chain variant insulin Wakayama.
Wan ZL; Huang K; Xu B; Hu SQ; Wang S; Chu YC; Katsoyannis PG; Weiss MA
Biochemistry; 2005 Apr; 44(13):5000-16. PubMed ID: 15794638
[TBL] [Abstract][Full Text] [Related]
28. Solution structure of the superactive monomeric des-[Phe(B25)] human insulin mutant: elucidation of the structural basis for the monomerization of des-[Phe(B25)] insulin and the dimerization of native insulin.
Jørgensen AM; Olsen HB; Balschmidt P; Led JJ
J Mol Biol; 1996 Apr; 257(3):684-99. PubMed ID: 8648633
[TBL] [Abstract][Full Text] [Related]
29. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
Nakagawa SH; Tager HS
J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
[TBL] [Abstract][Full Text] [Related]
30. Comparative 2D NMR studies of human insulin and des-pentapeptide insulin: sequential resonance assignment and implications for protein dynamics and receptor recognition.
Hua QX; Weiss MA
Biochemistry; 1991 Jun; 30(22):5505-15. PubMed ID: 2036420
[TBL] [Abstract][Full Text] [Related]
31. Solution structure of an engineered insulin monomer at neutral pH.
Olsen HB; Ludvigsen S; Kaarsholm NC
Biochemistry; 1996 Jul; 35(27):8836-45. PubMed ID: 8688419
[TBL] [Abstract][Full Text] [Related]
32. Structural determinants of ligand recognition by type I insulin-like growth factor receptors: use of semisynthetic insulin analog probes.
Cara JF; Nakagawa SH; Tager HS
Endocrinology; 1988 Jun; 122(6):2881-7. PubMed ID: 2967179
[TBL] [Abstract][Full Text] [Related]
33. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions.
Mirmira RG; Tager HS
Biochemistry; 1991 Aug; 30(33):8222-9. PubMed ID: 1868095
[TBL] [Abstract][Full Text] [Related]
34. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
[TBL] [Abstract][Full Text] [Related]
35. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions.
Nakagawa SH; Tager HS
Biochemistry; 1992 Mar; 31(12):3204-14. PubMed ID: 1554705
[TBL] [Abstract][Full Text] [Related]
36. Receptor binding and biological activity of [SerB24]-insulin, an abnormal mutant insulin.
Kobayashi M; Haneda M; Maegawa H; Watanabe N; Takada Y; Shigeta Y; Inouye K
Biochem Biophys Res Commun; 1984 Feb; 119(1):49-57. PubMed ID: 6367745
[TBL] [Abstract][Full Text] [Related]
37. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution.
Shoelson S; Fickova M; Haneda M; Nahum A; Musso G; Kaiser ET; Rubenstein AH; Tager H
Proc Natl Acad Sci U S A; 1983 Dec; 80(24):7390-4. PubMed ID: 6424111
[TBL] [Abstract][Full Text] [Related]
38. Extending Halogen-based Medicinal Chemistry to Proteins: IODO-INSULIN AS A CASE STUDY.
El Hage K; Pandyarajan V; Phillips NB; Smith BJ; Menting JG; Whittaker J; Lawrence MC; Meuwly M; Weiss MA
J Biol Chem; 2016 Dec; 291(53):27023-27041. PubMed ID: 27875310
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the dynamic behavior of monomeric and dimeric insulin shows structural rearrangements in the active monomer.
Zoete V; Meuwly M; Karplus M
J Mol Biol; 2004 Sep; 342(3):913-29. PubMed ID: 15342246
[TBL] [Abstract][Full Text] [Related]
40. Altering the association properties of insulin by amino acid replacement.
Brems DN; Alter LA; Beckage MJ; Chance RE; DiMarchi RD; Green LK; Long HB; Pekar AH; Shields JE; Frank BH
Protein Eng; 1992 Sep; 5(6):527-33. PubMed ID: 1438163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
